Portal de Periódicos da CAPES

Effect of Anti-IgE Therapy in Patients with Peanut Allergy

2003; Massachusetts Medical Society; Volume: 348; Issue: 11 Linguagem: Inglês

10.1056/nejmoa022613

1533-4406

Donald Y.M. Leung, Hugh A. Sampson, John W. Yunginger, A. Wesley Burks, Lynda C. Schneider, Cornelis H. Wortel, Frances M. Davis, John D. Hyun, William Shanahan,

Allergic Rhinitis and Sensitization

Peanut-induced anaphylaxis is an IgE-mediated condition that is estimated to affect 1.5 million people and cause 50 to 100 deaths per year in the United States. TNX-901 is a humanized IgG1 monoclonal antibody against IgE that recognizes and masks an epitope in the CH3 region of IgE responsible for binding to the high-affinity Fcε receptor on mast cells and basophils.